Printer Friendly

Vaxart commences preclinical testing of Zika virus oral vaccine.

M2 PHARMA-March 7, 2016-Vaxart commences preclinical testing of Zika virus oral vaccine

(C)2016 M2 COMMUNICATIONS

United States-based Vaxart has started preclinical testing of an oral vaccine for Zika virus, it was reported on Friday.

The company's vaccine platform allows delivery of recombinant vaccines using a room temperature-stable tablet that can be shipped and stored without refrigeration, and is ideally suited for viruses such as Zika.

Vaxart chief executive officer (CEO), Wouter Latour, MD said, 'Vaxart is responding to the global call-to-action to develop a Zika vaccine given the rapid spread of the disease and the devastating impact on pregnant women and infants. A tablet vaccine for Zika virus could offer tremendous public health benefits for affected and at-risk regions. We are engaging with government agencies, industry partners and NGOs, and intend to work together with them to develop a potential vaccine modality against Zika virus.'

Zika virus is a mosquito-borne disease that causes mild flu-like symptoms in most people. In pregnant women it may be linked to an increased rate of microencephaly, a neurodevelopmental disorder characterized by a smaller-than-normal head and brain size.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 7, 2016
Words:195
Previous Article:Zimmer Biomet enters into exclusive global distribution agreement with CelgenTek Innovations for unique fracture fixation and void-filling solution.
Next Article:Otonomy commences Otiprio phase two clinical trial.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters